SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Michelsen B.)
 

Sökning: WFRF:(Michelsen B.) > One-Year Treatment ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006479naa a2200685 4500
001oai:gup.ub.gu.se/315575
003SwePub
008240528s2022 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:efaeb55e-dfe7-46ea-8366-6358bd48644d
009oai:prod.swepub.kib.ki.se:148958620
0247 a https://gup.ub.gu.se/publication/3155752 URI
0247 a https://doi.org/10.1002/acr.245232 DOI
0247 a https://lup.lub.lu.se/record/efaeb55e-dfe7-46ea-8366-6358bd48644d2 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1489586202 URI
040 a (SwePub)gud (SwePub)lud (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Glintborg, B.u University of Copenhagen4 aut
2451 0a One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses
264 c 2022-03-08
264 1b Wiley,c 2022
520 a Objective To describe baseline characteristics and to compare treatment effectiveness of secukinumab versus tumor necrosis factor inhibitors (TNFi) in patients with spondyloarthritis (SpA) using adalimumab as the main comparator. Methods This was an observational, prospective cohort study. Patients with SpA (clinical ankylosing spondylitis, nonradiographic axial SpA, or undifferentiated SpA) starting secukinumab or a TNFi during 2015-2018 were identified from 5 Nordic clinical rheumatology registries. Data on comorbidities and extraarticular manifestations (psoriasis, uveitis, and inflammatory bowel disease) were captured from national registries (data available in 94% of patients) and included in multivariable analyses. We assessed 1-year treatment retention (crude survival curves, adjusted hazard ratios [HRadj] for treatment discontinuation) and 6-month response rates (Ankylosing Spondylitis Disease Activity Score [ASDAS] score <2.1, Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] <40 mm, crude/LUNDEX-adjusted, adjusted logistic regression analyses with odds ratios [ORs]) stratified by line of biologic treatment (first, second, and third plus). Results In total, 10,853 treatment courses (842 secukinumab and 10,011 TNFi, of which 1,977 were adalimumab) were included. The proportions of patients treated with secukinumab during the first, second, and third-plus lines of treatment were 1%, 6%, and 22%, respectively). Extraarticular manifestations varied across treatments, while other baseline characteristics were largely similar. Secukinumab had a 1-year retention comparable to adalimumab as a first or second line of treatment but poorer as a third-plus line of therapy (secukinumab 56% [95% confidence interval (95% CI) 51-61%] versus adalimumab 70% [95% CI 64-75%]; HRadj 1.43 [95% CI 1.12-1.81]). Across treatment lines, secukinumab had poorer estimates for 6-month response rates than adalimumab, statistically significantly only for the third-plus line (adjusted analyses: ASDAS score <2.1 OR 0.56 [95% CI 0.35-0.90]; BASDAI <40 mm OR 0.62 [95% CI 0.41-0.95]). Treatment outcomes varied across the 5 TNFi. Conclusion Secukinumab was mainly used in biologics-experienced patients with SpA. Secukinumab and adalimumab performed similarly in patients who had failed a first biologic, although with increasing prior biologic exposure, adalimumab was superior.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng
653 a ankylosing-spondylitis
653 a axial spondyloarthritis
653 a rheumatoid-arthritis
653 a etanercept
653 a adalimumab
653 a infliximab
653 a psoriasis
653 a efficacy
653 a Rheumatology
7001 a Lindström, Ulfu Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research,Sahlgrenska Academy4 aut0 (Swepub:gu)xlulfn
7001 a Di Giuseppe, D.u Karolinska Institutet,Karolinska Institute4 aut
7001 a Provan, S. A.u Diakonhjemmet Hospital4 aut
7001 a Gudbjornsson, B.u University of Iceland4 aut
7001 a Hetland, M. L.u University of Copenhagen4 aut
7001 a Michelsen, B.u Diakonhjemmet Hospital4 aut
7001 a Wallman, Johan K.u Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund Arthritis Research Group (LARG),Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)med-jnk
7001 a Aaltonen, K.4 aut
7001 a Hokkanen, A. M.u Helsinki University Central Hospital4 aut
7001 a Nordstrom, D.u Helsinki University Central Hospital4 aut
7001 a Jorgensen, T. S.u Copenhagen University Hospital4 aut
7001 a Hansen, R. L.u Copenhagen University Hospital4 aut
7001 a Geirsson, A. J.u Karolinska Institutet,Karolinska Institute4 aut
7001 a Gron, K. L.u Copenhagen University Hospital4 aut
7001 a Krogh, N. S.4 aut
7001 a Askling, J.4 aut
7001 a Kristensen, L. E.u Copenhagen University Hospital4 aut
7001 a Jacobsson, Lennart T. H.,d 1954u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research,Sahlgrenska Academy4 aut0 (Swepub:gu)xjacle
7102 a University of Copenhagenb Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning4 org
7730 t Arthritis Care & Researchd : Wileyg 74:5, s. 748-758q 74:5<748-758x 2151-464Xx 2151-4658
8564 u http://dx.doi.org/10.1002/acr.24523y FULLTEXT
8564 8u https://gup.ub.gu.se/publication/315575
8564 8u https://doi.org/10.1002/acr.24523
8564 8u https://lup.lub.lu.se/record/efaeb55e-dfe7-46ea-8366-6358bd48644d
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:148958620

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy